Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Merck Sharp & Dohme,Letermovir,"Cytomegalovirus infection prophylaxis, stem cell transplant patients",Letermovir,Options for investment,,Infections - Agents for Systemic Use
